Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study.
Tanguay M, Roy J, Su J, Gul E, Reece D, Venner CP, White D, Chu MP, Jimenez-Zepada VH, Song K, Mccurdy A, Mian H, Sebag M, Bergstrom D, Stakiw J, Reiman A, Kotb R, Aslam M, Kaedbey R, Louzada M, LeBlanc R. Tanguay M, et al. Among authors: sebag m. Cancer Med. 2024 Nov;13(21):e70332. doi: 10.1002/cam4.70332. Cancer Med. 2024. PMID: 39499045 Free PMC article.
Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014.
Bahlis NJ, Samaras C, Reece D, Sebag M, Matous J, Berdeja JG, Shustik J, Schiller GJ, Ganguly S, Song K, Seet CS, Acosta-Rivera M, Bar M, Quick D, Fonseca G, Liu H, Gentili C, Singh P, Siegel D. Bahlis NJ, et al. Among authors: sebag m. Clin Lymphoma Myeloma Leuk. 2024 Dec;24(12):852-862. doi: 10.1016/j.clml.2024.07.014. Epub 2024 Aug 8. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39237427 Free article. Clinical Trial.
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.
Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R, Orloff G, Jakubowiak A, Niesvizky R, Liles D, Berdeja J, Levy M, Wolf J, Usmani SZ; MMRF CoMMpass Network; Christofferson AW, Nasser S, Aldrich JL, Legendre C, Benard B, Miller C, Turner B, Kurdoglu A, Washington M, Yellapantula V, Adkins JR, Cuyugan L, Boateng M, Helland A, Kyman S, McDonald J, Reiman R, Stephenson K, Tassone E, Blanski A, Livermore B, Kirchhoff M, Rohrer DC, D'Agostino M, Gamella M, Collison K, Stumph J, Kidd P, Donnelly A, Zaugg B, Toone M, McBride K, DeRome M, Rogers J, Craig D, Liang WS, Gutierrez NC, Jewell SD, Carpten J, Anderson KC, Cho HJ, Auclair D, Lonial S, Keats JJ. Skerget S, et al. Nat Genet. 2024 Sep;56(9):1878-1889. doi: 10.1038/s41588-024-01853-0. Epub 2024 Aug 19. Nat Genet. 2024. PMID: 39160255 Free PMC article.
Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database.
Venner CP, Duggan P, Song K, Reece D, Sharma S, Su J, Jimenez-Zepeda VH, McCurdy A, Louzada M, Mian H, Sebag M, White D, Stakiw J, Kotb R, Aslam M, Reiman A, Gul E, Chu MP, Bergstrom D, LeBlanc R. Venner CP, et al. Among authors: sebag m. Transplant Cell Ther. 2024 Sep;30(9):889-901. doi: 10.1016/j.jtct.2024.06.030. Epub 2024 Jul 4. Transplant Cell Ther. 2024. PMID: 38971462
COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies.
Bhella S, Wilkin AM, Hueniken K, Vijenthira A, Sebag M, Wang P, Hicks LK, Hay AE, Assouline S, Fraser G, Balitsky A, Mangel J, Owen C, Reiman A, Sehn L, Sutherland H, Zhang T, Arnold C, Leite T, McCarthy E, Cooper C, Langlois MA, Arianne Buchan C; VIP Study Investigators. Bhella S, et al. Among authors: sebag m. Vaccine. 2024 Oct 24;42(24):126074. doi: 10.1016/j.vaccine.2024.06.041. Epub 2024 Jun 28. Vaccine. 2024. PMID: 38944577 Free article.
Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) database.
Kaedbey R, Reece D, Venner CP, McCurdy A, Su J, Chu M, Louzada M, Jimenez-Zepeda VH, Mian H, Song K, Sebag M, Stakiw J, White D, Reiman A, Aslam M, Kotb R, Bergstrom D, Gul E, LeBlanc R. Kaedbey R, et al. Among authors: sebag m. EJHaem. 2024 Apr 29;5(3):474-484. doi: 10.1002/jha2.894. eCollection 2024 Jun. EJHaem. 2024. PMID: 38895063 Free PMC article.
Long-term outcomes of iris-sutured subluxated intraocular lenses.
Nayman T, Milad D, Sebag M. Nayman T, et al. Among authors: sebag m. Indian J Ophthalmol. 2024 Feb 1;72(Suppl 2):S218-S223. doi: 10.4103/IJO.IJO_3397_22. Epub 2024 Jan 25. Indian J Ophthalmol. 2024. PMID: 38271417 Free PMC article.
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.
Visram A, De La Torre A, White D, Su J, Masih-Khan E, Chu M, Jimenez-Zepeda V, McCurdy A, LeBlanc R, Song K, Mian H, Louzada M, Sebag M, Bergstrom D, Stakiw J, Reiman A, Kotb R, Aslam M, Venner C, Kaedbey R, Gul E, Reece D. Visram A, et al. Among authors: sebag m. Blood Cancer J. 2023 Dec 8;13(1):181. doi: 10.1038/s41408-023-00946-z. Blood Cancer J. 2023. PMID: 38065967 Free PMC article.
108 results